Clinical proteomics: new diagnostic possibilities of mass spectrometry

A mass spectrometric method of serum amyloyd A (SAA) identification was developed. SAA is a protein, characteristic marker for ovarian cancer diagnostics. Its determination was accomplished directly in the human blood serum by regulated trypsinolysis without a preliminary separation. New approaches to quantitative determination of this protein in blood sera with using of concentration of its tryptic fragment (67-87) SAA, present in hydrolysates, were developed. Besides mass spectrometric method of determination of α2-macroglobulin (α2-M) in blood sera and plasma were developed. Concentrations of α2-M in blood sera under ovarian cancer and in blood plasma under Alzheimer disease were measured using developed methods. It was shown that concentration of α2-M significantly increases under ovarian cancer and decreases under Alzheimer disease relatively of donor's blood sera.